Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Friedrich Scheiflinger

Showing results (41-50 of 85) with videos related to

Pageof 9
Sort By:
British Journal of Haematology|November 18, 2003
Evaluation of the haemostatic potential of factor VIII-heparin cofactor II hybrid proteins in a mouse modelSimone Schatz, Peter L Turecek, Christian Fiedler, et al.
Journal of the American Society of Nephrology : JASN|April 1, 2005
Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvementMarina Noris, Sara Bucchioni, Miriam Galbusera, et al.
BMC Proceedings|March 1, 2012
Expression of recombinant human coagulation factors VII (rFVII) and IX (rFIX) in various cell types, glycosylation analysis, and pharmacokinetic comparisonErnst Böhm, Michael Dockal, Michael Graninger, et al.
Antibodies (Basel, Switzerland)|September 24, 2019
Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and PharmacokineticsPatrice Douillard, Michael Freissmuth, Gerhard Antoine, et al.
BMC Biotechnology|September 19, 2015
Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cellsErnst Böhm, Birgit K Seyfried, Michael Dockal, et al.
Blood|August 19, 2009
von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental strokeBing-Qiao Zhao, Anil K Chauhan, Matthias Canault, et al.
Pharmaceutical Research|April 3, 2019
How Full-Length FVIII Benefits from Its Heterogeneity - Insights into the Role of the B-DomainJulia Anzengruber, Martin Feichtinger, Philipp Bärnthaler, et al.
Arthritis Care & Research|April 28, 2011
Thrombotic thrombocytopenic purpura in IgG4-related disease with severe deficiency of ADAMTS-13 activity and IgG4 autoantibody against ADAMTS-13Takako Saeki, Tomoyuki Ito, Akira Youkou, et al.
Transfusion|December 3, 2003
Immunochemical detection of prion protein on dipsticks prepared with crystalline bacterial cell-surface layersDirk Völkel, Klaus Zimmermann, Andreas Breitwieser, et al.
The Journal of Experimental Medicine|March 15, 2006
Systemic antithrombotic effects of ADAMTS13Anil K Chauhan, David G Motto, Colin B Lamb, et al.
Pageof 9

Showing results (41-50 of 85) with videos related to

Sort By:
Pageof 9
British Journal of Haematology|November 18, 2003
Evaluation of the haemostatic potential of factor VIII-heparin cofactor II hybrid proteins in a mouse modelSimone Schatz, Peter L Turecek, Christian Fiedler, et al.
Journal of the American Society of Nephrology : JASN|April 1, 2005
Complement factor H mutation in familial thrombotic thrombocytopenic purpura with ADAMTS13 deficiency and renal involvementMarina Noris, Sara Bucchioni, Miriam Galbusera, et al.
BMC Proceedings|March 1, 2012
Expression of recombinant human coagulation factors VII (rFVII) and IX (rFIX) in various cell types, glycosylation analysis, and pharmacokinetic comparisonErnst Böhm, Michael Dockal, Michael Graninger, et al.
Antibodies (Basel, Switzerland)|September 24, 2019
Optimization of an Antibody Light Chain Framework Enhances Expression, Biophysical Properties and PharmacokineticsPatrice Douillard, Michael Freissmuth, Gerhard Antoine, et al.
BMC Biotechnology|September 19, 2015
Differences in N-glycosylation of recombinant human coagulation factor VII derived from BHK, CHO, and HEK293 cellsErnst Böhm, Birgit K Seyfried, Michael Dockal, et al.
Blood|August 19, 2009
von Willebrand factor-cleaving protease ADAMTS13 reduces ischemic brain injury in experimental strokeBing-Qiao Zhao, Anil K Chauhan, Matthias Canault, et al.
Pharmaceutical Research|April 3, 2019
How Full-Length FVIII Benefits from Its Heterogeneity - Insights into the Role of the B-DomainJulia Anzengruber, Martin Feichtinger, Philipp Bärnthaler, et al.
Arthritis Care & Research|April 28, 2011
Thrombotic thrombocytopenic purpura in IgG4-related disease with severe deficiency of ADAMTS-13 activity and IgG4 autoantibody against ADAMTS-13Takako Saeki, Tomoyuki Ito, Akira Youkou, et al.
Transfusion|December 3, 2003
Immunochemical detection of prion protein on dipsticks prepared with crystalline bacterial cell-surface layersDirk Völkel, Klaus Zimmermann, Andreas Breitwieser, et al.
The Journal of Experimental Medicine|March 15, 2006
Systemic antithrombotic effects of ADAMTS13Anil K Chauhan, David G Motto, Colin B Lamb, et al.
Pageof 9